When will adagrasib be available in China?

As a prescription drug, Adagrasib (Adagrasib) is mainly targeted at adult patients with non-small cell lung cancer. This is especially true for patients whose cancer has spread to other parts of the body, cannot be cured by surgery, and whose tumors carry the abnormal KRAS G12C gene. For such patients, if they have already received at least one cancer treatment but the effect was not good, adagrasib may bring them new treatment hope.

The KRAS gene produces a protein under normal circumstances, but when KRAS undergoes a G12C mutation, it triggers a chain reaction that leads to cancer. It is by targeting this mutation that adagrasib inhibits the growth and spread of tumors. This mechanism gives adagrasib a unique advantage in treating cancers with KRAS G12C mutations. Before using adagrasib, doctors will conduct comprehensive testing on patients to ensure the safety and effectiveness of the drug. As for pediatric patients, it is currently unclear whether adagrasib is suitable, which requires further clinical research and data support.

Adagrasib demonstrated impressive efficacy in large open-label trials. The study results showed that in patients with refractory NSCLC carrying KRAS G12C mutations, adagrasib was able to induce an objective response of 43% and was well tolerated. This data provides strong support for the clinical application of adagrasib.

The original drug of adagrasibu is not currently available in China, but relevant clinical studies may have been conducted in China. As time goes by, adagrasib is likely to be available for sale in China.